Home Featured Page 162

Featured

Latest

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Numinus to Acquire Novamind, Creating the North American Industry Leader in...

PT310 – Omar Thomas – Vital Psychedelic Conversations

Could the Sonoran Desert Toad Cure Narcissism?

Mydecine Announces Reverse Stock-Split

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and...

PT309 – Jon Dennis, Esq. – Oregon’s Measure 109 and the...

Numinus to Acquire Novamind, Creating the North American Industry Leader in...

PT308 – Dr. Ido Cohen, PsyD – Vital Psychedelic Conversations

Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by...

Entheon Biomedical Announces Non-Brokered Private Placement Financing

1...161162163...291 Page 162 of 291

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Numinus to Acquire Novamind, Creating the North American Industry Leader in...

PT310 – Omar Thomas – Vital Psychedelic Conversations

Could the Sonoran Desert Toad Cure Narcissism?

Mydecine Announces Reverse Stock-Split

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and...

PT309 – Jon Dennis, Esq. – Oregon’s Measure 109 and the...

Numinus to Acquire Novamind, Creating the North American Industry Leader in...

PT308 – Dr. Ido Cohen, PsyD – Vital Psychedelic Conversations

Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by...

Entheon Biomedical Announces Non-Brokered Private Placement Financing

EDITOR PICKS

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY